Ibrutinib-induced severe liver injury.

Nandikolla, Amara G; Derman, Olga; Nautsch, Deborah; Liu, Qiang; Massoumi, Hatef; Venugopal, Sangeetha; Braunschweig, Ira; Janakiram, Murali

Nandikolla, Amara G; Derman, Olga; Nautsch, Deborah; Liu, Qiang; Massoumi, Hatef; Venugopal, Sangeetha; Braunschweig, Ira; Janakiram, Murali.

Afiliação

Nandikolla AG; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Derman O; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Nautsch D; Department of Pathology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Liu Q; Department of Pathology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Massoumi H; Department of Hepatology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Venugopal S; Department of Medicine Montefiore Medical Center Bronx New York USA.
Braunschweig I; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.
Janakiram M; Department of Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA.

Clin Case Rep ; 5(6): 735-738, 2017 06.

Article em En | MEDLINE | ID: mdl-28588800

ABSTRACT

ABSTRACT

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

Palavras-chave

Chronic lymphocytic leukemia; Richter's syndrome; ibrutinib; liver injury; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links